Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Radiology, Weill Cornell Medical College, New York, NY.
Semin Hematol. 2018 Jan;55(1):22-32. doi: 10.1053/j.seminhematol.2018.02.009. Epub 2018 Mar 5.
Imaging plays a key role in assessment of myeloma. Osteolytic bone lesions are optimally assessed using structural imaging, however the structural changes lag the functional changes in the disease. Functional imaging with fluoro deoxy glucose (FDG) positron emission tomography (PET) computerized tomography (CT) is useful in assessment of high-risk myeloma. FDG PET provides prognostic information and is helpful in monitoring response to therapy. However, it is nonspecific and may not be optimal in assessing treatment response to immunotherapeutic agents. Imaging with targeted agents may allow for better assessment of changes from therapy, that is based on the specific targeted mechanism. ImmunoPET imaging is a novel method to assess targeting of specific antigen by therapeutic antibodies. This review summarizes the role of functional imaging and development of novel immunoPET agents for assessment of treatment response and residual disease.
影像学在骨髓瘤的评估中起着关键作用。溶骨性骨病变最好通过结构影像学来评估，然而，疾病的功能变化滞后于结构变化。氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）计算机断层扫描（CT）的功能影像学在高危骨髓瘤的评估中很有用。FDG-PET 提供预后信息，并有助于监测对治疗的反应。然而，它是非特异性的，在评估免疫治疗药物的治疗反应方面可能不是最佳的。靶向药物的影像学检查可能可以更好地评估基于特定靶向机制的治疗反应变化。免疫 PET 成像技术是一种评估治疗性抗体针对特定抗原的靶向性的新方法。本综述总结了功能影像学的作用和新型免疫 PET 药物的开发，用于评估治疗反应和残留疾病。
